ECCO IBD Curriculum

6.11. Appreciates the role of stopping medical therapies in IBD and the appropriate timing / patient population in whom drugs can be stopped.
Exit StrategiesECCO e-Learning
Year: 2017
Authors: Johan Burisch, Ren Mao, Edyta Szymanska, Glen Doherty

This course has been developed for gastroenterologists, surgeons, paediatricians, pathologists and other interdisciplinary medical experts interested in Inflammatory Bowel Disease(s) (IBD). One major aim of this e-learning activity is to provide evidence-based guidance for clinical practice so that physicians can make informed decisions in partnership with their patients regarding their optimal exit strategies.

After this course you will:

  • To recognise risks, benefits and timing of stopping anti-TNF used as monotherapy or in combination with IM in IBD.
  • To know optimal monitoring following withdrawal of biologic therapy

Crohn's disease: Perianal disease e-Coursee-Course
Year: 2020
Authors: Federica Furfaro, Kostas Katsanos, Pascal Juillerat, Pierre Ellul

This course has been developed by physicians who had recently participated in the writing of the ECCO Crohn's disease consensus Guidelines. This course is intended for those who are interested in Inflammatory Bowel Disease(s) (IBD). One major aim of this e-learning activity is to increase competence and knowledge with regard to Perianal disease in order to improve patient outcomes.

After this case you will:

  • To appreciate the Crohn’s disease natural history
  • To appreciate the rationale behind specific treatment decisions
  • To understand the right investigations to prescribe to Crohn’s disease patient in specific settings
  • To learn appropriate clinical management of Crohn’s disease patients with perianal involvement

Luminal Crohn's disease e-Coursee-Course
Year: 2020
Authors: João Sabino, Bram Verstockt, Kostas Katsanos, Pascal Juillerat, Pierre Ellul

This course has been developed by physicians who had recently participated in the writing of the ECCO Crohn's disease consensus Guidelines. This course is intended for those who are interested in Inflammatory Bowel Disease(s) (IBD). One major aim of this e-learning activity is to increase competence and knowledge with regard to Luminal disease in order to improve patient outcomes.

Upon completion of this case you will:

  • Know the evidence for induction of remission in mild-to-moderate Crohn’s disease;
  • Know the evidence for maintaining remission in  Crohn’s disease;
  • Know the evidence on how to react upon disease flares, immediately after induction therapy or during maintenance therapy; 
  • Understand the benefits and risks of several medical therapies;
  • Achieve familiarity how to use immunomodulatory agents in mono- or combination therapy;
  • Achieve familiarity how to monitor Crohn’s disease patients who initiated medical therapy or who underwent surgery;
  • Recognise indications for surgical management.

UC Update e-Coursee-Course
Year: 2016
Authors: Gianluca Pellino, Tim Raine, Dominik Bettenworth, Johan Burisch, Kristzina Gecse, Pieter Hindryck, Antonio López-Sanromán

This course is designed for gastroenterologists, surgeons, paediatricians, pathologists and other interdisciplinary medical experts interested in Inflammatory Bowel Disease(s) (IBD). One major aim of this e-learning activity is to increase competence and knowledge with regard to the prediction, diagnosis and management of Ulcerative Colitis (UC) patients and to harmonise diagnostics and treatment in order to improve patient outcomes.

Upon completion of this activity learners will:

  • Have insights into the basic epidemiology of ulcerative colitis
  • Know current treatment options for severe ulcerative colitis, including colectomy
  • Be able to use ciclosporin correctly in severe ulcerative colitis
  • Understand when to order thiopurine methyltransferase (TPMT) activity when starting azathioprine

Anti-TNFEducational Audio Podcasts
Year: 2019
Authors: Christian Maaser
ThiopurinesEducational Audio Podcasts
Year: 2019
Authors: Pascal Juillerat
Anti-TNF agents15th IBD Intensive Advanced Course
Year: 2017
Authors: Baert F.
Anti TNF drug levels, Anti drug antibodies, Therapeutic drug monitoring, Anti-TNF agents
Files: 1
Methotrexate15th IBD Intensive Advanced Course
Year: 2017
Authors: Juillerat P.
Crohn's disease, Ulcerative colitis, Therapeutic drug monitoring, Methotrexate
Files: 1
Thiopurines15th IBD Intensive Advanced Course
Year: 2017
Authors: Irving P.
Pharmacogenetics, Pharmacokinetics, Thiopurines (AZA/MP)
Files: 1
Ustekinumab15th IBD Intensive Advanced Course
Year: 2017
Authors: Ferrante M.
Crohn's disease, Disease activity Indices, Ustekinumab, Colonoscopy
Files: 1
Vedolizumab15th IBD Intensive Advanced Course
Year: 2017
Authors: Lindsay J.
Therapeutic drug monitoring, Vedolizumab
Files: 1
Understanding Cancer RiskTalking Heads
Year: 2016
Authors: Ebbe Langholz, Tine Jess
When to stop Biologics in IBDTalking Heads
Year: 2016
Authors: John Mansfield, Javier Gisbert, Edouard Louis